ALGIPHARMA AS
Operating
Forskning og kommersialisering av forskningsprosjekter og
forskningsresultater knyttet til alginater og annen bioteknologi og
virksomhet i tilknytning til detter, herunder deltakelse i andre
virksomheter gjennom aksjeeie eller på annen måte.
Kommersialisering av forskningsprosjekter og
forskningsresultater utviklet i samarbeid mellom
Nobipol forskningsstiftelse og Protan Biopolymer
AS, herunder deltagelse i andre virksomheter
gjennom aksjeeie eller på annen måte.
Organization
- CEO
- YP
- Chairman of the board
- AD
Arne Dessen1959
- Years since formation
- 31 years
- since Feb 20, 1995
- Type
- Limited company
- VAT registered
- Yes
- Number of employees
- 6
Ownership
- Number of shares and share classes
- 10,421,261
- 1 share class
- Total number of shareholders
- 1
- company
- Belongs to group of
Financials
- Total operating income 2025
- 29,219
- NOK
- Annual total result 2025
- -8,676,949
- NOK
Last update: Jul 25, 2026
Management
Management / administration
| Name | Role | Shares |
|---|---|---|
YP | Managing Director/CEO | 81.91 % indirectly |
Board
| Name | Role | Shares |
|---|---|---|
AD 1959 | Chairman | 1.26 % indirectly |
| Board Member | - | |
YP | Board Member | 81.91 % indirectly |
Others
| Name | Role | Shares |
|---|---|---|
| Auditor | - |
Top 10 individual shareholders
| Name | Role | Shares |
|---|---|---|
YP | Managing Director/CEO, Board Member | 81.91 % indirectly |
CA | - | 9.15 % indirectly |
AD 1959 | Chairman | 1.26 % indirectly |
Last update: Oct 22, 2025
Ownership
Company shareholders
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
| Ordinary shares | 10,421,261 | 100 % |
Last update: Jun 2, 2025
Group structure
- Total operating income 2025: NOK 0Operating profit 2025: NOK -91,189Employees: 0
Financials
in NOK
Summary
| Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
Total operating income | 29,219 | 5,738 | 85,940 | 40,000 | 64,500 |
Annual Total Result | -8,676,949 | -8,962,504 | -9,715,740 | -7,073,262 | -10,657,673 |
Total assets | 0 | 207,325,830 | 188,878,585 | 173,350,922 | 155,526,168 |
Total liabilities | 0 | 31,180,343 | 60,290,624 | 145,462,676 | 120,564,660 |
Total equity | 0 | 176,145,487 | 128,587,961 | 27,888,246 | 34,961,508 |
P&L
| Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
Total operating income | 29,219 | 5,738 | 85,940 | 40,000 | 64,500 |
Total operating costs | 6,754,429 | 6,864,163 | 5,929,616 | 7,984,794 | 6,701,441 |
Operating result | -6,725,210 | -6,858,426 | -5,843,676 | -7,944,794 | -6,636,941 |
Financial income/costs | -1,951,739 | -2,104,079 | -3,987,833 | 871,531 | -4,020,732 |
Profit before tax | -8,676,949 | -8,962,504 | -9,831,509 | -7,073,262 | -10,657,673 |
Total tax & extraordinary income/cost | 0 | 0 | -115,769 | 0 | 0 |
Annual Total Result | -8,676,949 | -8,962,504 | -9,715,740 | -7,073,262 | -10,657,673 |
Balance overview
| Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
Total fixed assets | 0 | 201,536,517 | 181,567,841 | 168,449,203 | 149,488,068 |
Total current assets | 0 | 5,789,313 | 7,310,744 | 4,901,720 | 6,038,100 |
Total assets | 0 | 207,325,830 | 188,878,585 | 173,350,922 | 155,526,168 |
Short term debt | 0 | 16,356,455 | 12,624,763 | 17,695,462 | 8,304,754 |
Long term debt | 0 | 14,823,888 | 47,665,861 | 127,767,215 | 112,259,905 |
Total liabilities | 0 | 31,180,343 | 60,290,624 | 145,462,676 | 120,564,660 |
Contributed capital | 0 | 176,145,487 | 128,587,961 | 27,888,246 | 34,961,508 |
Retained earnings | 0 | 0 | 0 | 0 | 0 |
Total equity | 0 | 176,145,487 | 128,587,961 | 27,888,246 | 34,961,508 |
Total equity and liabilities | 0 | 207,325,830 | 188,878,585 | 173,350,922 | 155,526,168 |
Classification
21st company classification
BETA
Small company
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises